<DOC>
	<DOCNO>NCT02910050</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety bicalutamide aromatase inhibitor ER ( + ) /AR ( + ) /HER2 ( - ) metastatic breast cancer patient disease progression treatment aromatase inhibitor .</brief_summary>
	<brief_title>Bicalutamide Plus Aromatase Inhibitors ER ( + ) /AR ( + ) /HER2 ( - ) Metastatic Breast Cancer</brief_title>
	<detailed_description>Androgen receptor ( AR ) closely related molecular type , treatment prognosis breast cancer . Over 70 % breast cancer express androgen receptor . And estrogen receptor positive breast cancer cell resistant Aromatase inhibitor change androgen receptor dependent . So AR may new target treatment breast cancer . Bicalutamide selective androgen receptor inhibitor clinical benefit rate 19 % median progression free survival 12 week ER-/AR+ metastatic breast cancer . This study aim evaluate efficacy safety bicalutamide aromatase inhibitor ER+/AR+/HER- metastatic breast cancer patient disease progression treatment AI .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients histologically confirm estrogen receptor positive , androgen positive HER2 negative breast cancer Metastatic unresectable locally advanced disease Age 18 year Postmenopausal status （continuous use luteinizing hormone release hormone ( LHRH ) analogue available） Patient must disease progression treatment Aromatase inhibitor . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 Life expectancy 3 month . Measurable disease accord RECIST version 1.1 bone metastasis Adequate hematological , hepatic function . Voluntarily sign date write informed consent prior study specific procedure . Patient lifethreatening visceral metastasis , extensive liver metastasis , brain meningeal metastasis Concomitant diseases/conditions controllable , Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . History primary malignancy Resistant steroidal nonsteroidal aromatase Inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>androgen receptor</keyword>
	<keyword>bicalutamide</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>letrozole</keyword>
	<keyword>anastrozole</keyword>
	<keyword>exemestane</keyword>
</DOC>